Vigil Neuroscience, Inc. financial data

Symbol
VIGL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Forge Road, Suite 700, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.11K % -45%
Debt-to-equity 21 % +138%
Return On Equity -76 % -80.3%
Return On Assets -62.9 % -62.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.6M shares +10.5%
Common Stock, Shares, Outstanding 37.6M shares +4.82%
Entity Public Float 233M USD +688%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 40.6M shares +4.93%
Weighted Average Number of Shares Outstanding, Diluted 40.6M shares +4.93%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 62.1M USD +15.5%
General and Administrative Expense 28M USD +9.93%
Operating Income (Loss) -90.1M USD -13.7%
Nonoperating Income (Expense) 6.24M USD +90.5%
Net Income (Loss) Attributable to Parent -83.8M USD -10.4%
Earnings Per Share, Basic -2.12 USD/shares -5.47%
Earnings Per Share, Diluted -2.12 USD/shares -5.47%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.3M USD -36.5%
Marketable Securities, Current 49.4M USD -46%
Other Assets, Current 939K USD -20.3%
Assets, Current 90.2M USD -42.1%
Property, Plant and Equipment, Net 1.54M USD -19.1%
Operating Lease, Right-of-Use Asset 15.5M USD -8.05%
Other Assets, Noncurrent 295K USD
Assets 108M USD -38.2%
Accounts Payable, Current 1.42M USD -40%
Employee-related Liabilities, Current 2.25M USD +4.41%
Liabilities, Current 10.8M USD +31.7%
Operating Lease, Liability, Noncurrent 12.4M USD -7.23%
Liabilities 23.2M USD +7.51%
Accumulated Other Comprehensive Income (Loss), Net of Tax -26K USD +62.9%
Retained Earnings (Accumulated Deficit) -264M USD -46.5%
Stockholders' Equity Attributable to Parent 85.3M USD -44.6%
Liabilities and Equity 108M USD -38.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.9M USD +1.38%
Net Cash Provided by (Used in) Financing Activities 5.18M USD +2454%
Net Cash Provided by (Used in) Investing Activities 16.5M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 37.6M shares +4.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -231K USD +99.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.2M USD -35.9%
Deferred Tax Assets, Valuation Allowance 69.1M USD +63.8%
Deferred Tax Assets, Gross 73.5M USD +74%
Operating Lease, Liability 13.4M USD -5.65%
Depreciation 105K USD +369%
Payments to Acquire Property, Plant, and Equipment 492K USD +246%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -83.8M USD -10.3%
Lessee, Operating Lease, Liability, to be Paid 18.3M USD -9.14%
Property, Plant and Equipment, Gross 2.2M USD +74.8%
Operating Lease, Liability, Current 969K USD +20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.03M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.97M USD +3.04%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.9M USD -17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.09M USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 26.3M USD +41.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.09M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 4.42M USD +5959%
Share-based Payment Arrangement, Expense 9.93M USD +42.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%